Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited has announced the allowance of a core US patent for its onCARlytics platform, a significant step in securing its intellectual property in the major oncology market of the United States. This patent, which protects the method of composition and use of its CF33-CD19 oncolytic virotherapy in combination with CD19 targeting CAR T cell therapies, is valid until 2038. The patent strengthens Imugene’s position in the global healthcare market, following a similar patent allowance in China. The company’s ongoing OASIS trial in the US aims to further explore the potential of this technology in treating solid tumors.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing novel immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors. The company is working on a range of platform technologies, including an off-the-shelf CAR T cell therapy targeting CD19 for blood cancers, multiple B-cell vaccine candidates, and an oncolytic virotherapy aimed at treating various cancers in combination with standard care and emerging therapies.
Average Trading Volume: 22,896,452
Technical Sentiment Signal: Sell
Current Market Cap: A$112M
See more data about IMU stock on TipRanks’ Stock Analysis page.